Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Dupuy

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Journal of the American Academy of Dermatology|July 22, 2014
Syringotropic mycosis fungoides: clinical and histologic features, response to treatment, and outcome in 19 patientsAdèle de Masson, Maxime Battistella, Marie-Dominique Vignon-Pennamen, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
Immunity|July 21, 2016
CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone MiceAmanda Poissonnier, Doriane Sanséau, Matthieu Le Gallo, et al.
European Journal of Dermatology : EJD|May 29, 2010
A three-year-analysis of fixed drug eruptions in hospital settings in FranceNesrine Brahimi, Emilie Routier, Nadia Raison-Peyron, et al.
Journal of Medicinal Chemistry|October 7, 2011
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperoneFrançois Vallée, Chantal Carrez, Fabienne Pilorge, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trialMarie Véron, Sylvie Chevret, Jean-Jacques Grob, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.
Rheumatology (Oxford, England)|March 16, 2021
Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre studyAmandine Weill, Julie Delyon, Vincent Descamps, et al.
JCO Precision Oncology|December 24, 2021
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 TherapyLéa Dousset, Florence Poizeau, Caroline Robert, et al.
Cancer|October 23, 2019
Quality-of-life assessment in French patients with metastatic melanoma in real lifeMarguerite Kandel, Stéphane Dalle, Aurélie Bardet, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Journal of the American Academy of Dermatology|July 22, 2014
Syringotropic mycosis fungoides: clinical and histologic features, response to treatment, and outcome in 19 patientsAdèle de Masson, Maxime Battistella, Marie-Dominique Vignon-Pennamen, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
Immunity|July 21, 2016
CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone MiceAmanda Poissonnier, Doriane Sanséau, Matthieu Le Gallo, et al.
European Journal of Dermatology : EJD|May 29, 2010
A three-year-analysis of fixed drug eruptions in hospital settings in FranceNesrine Brahimi, Emilie Routier, Nadia Raison-Peyron, et al.
Journal of Medicinal Chemistry|October 7, 2011
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperoneFrançois Vallée, Chantal Carrez, Fabienne Pilorge, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trialMarie Véron, Sylvie Chevret, Jean-Jacques Grob, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.
Rheumatology (Oxford, England)|March 16, 2021
Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre studyAmandine Weill, Julie Delyon, Vincent Descamps, et al.
JCO Precision Oncology|December 24, 2021
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 TherapyLéa Dousset, Florence Poizeau, Caroline Robert, et al.
Cancer|October 23, 2019
Quality-of-life assessment in French patients with metastatic melanoma in real lifeMarguerite Kandel, Stéphane Dalle, Aurélie Bardet, et al.
Pageof 13